Relmada Therapeutics
RLMD
82 hedge funds and large institutions have $335M invested in Relmada Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 10 closing their positions.
1,377% more call options, than puts
Call options by funds: $17M | Put options by funds: $1.15M
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
12% more capital invested
Capital invested by funds: $298M → $335M (+$36.7M)
3% more funds holding
Funds holding: 80 → 82 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.4% less ownership
Funds ownership: 57.33% → 56.93% (-0.4%)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$10.2M |
| 2 |
VA
VR Adviser
New York
|
+$6.46M |
| 3 |
CAC
Cowen and Company
New York
|
+$5.84M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.91M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$8.57M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.94M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.85M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.08M |
| 5 |
Aviva
London,
United Kingdom
|
-$1.08M |
RLMD Hedge Fund Activity: Q1 2021 in Review
82 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2021, worth a combined $335M — up 12% from $298M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RLMD positions and 10 closed out — a net gain of 2 holders — while 19 added to existing stakes and 26 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $10.2M. The largest seller was Invesco, exiting entirely with an estimated $8.57M sold.
- 82 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2021, up from 80 in Q4 2020.
- Funds reported $335M of Relmada Therapeutics stock for Q1 2021, up 12% quarter-over-quarter.
- 12 funds opened new Relmada Therapeutics positions in Q1 2021 and 10 closed out, a net change of +2 holders.
- The largest Relmada Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $10.2M added.
- The largest Relmada Therapeutics seller in Q1 2021 was Invesco, an estimated $8.57M sold.
Based on aggregated 13F filings for Q1 2021.